This website is intended for healthcare professionals

Belzutifan

NICE approves first-ever drug treatment for patients with ‘life-threatening’ disease

In clinical trials, 95% of patients did not have further tumour growth after taking the drug, which is a ‘huge step forward in the treatment of the disease’

Why choose British Journal of Nursing?

BJN provides nurses with an evidence base for clinical practice and a platform for professional development. It shares the information and advice that is key to unlocking your full potential.

What's included

  • Clinical expertise

  • Peer-reviewed research

  • Best practice guidance

  • CPD support

Subscriptions start:

From £13.75 GBP